Drug Profile


Alternative Names: BX 807834; CI 1031; ZK 807834

Latest Information Update: 30 Aug 2004

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma; Pfizer
  • Class Anticoagulants; Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis; Unstable angina pectoris

Most Recent Events

  • 15 Jun 2004 Discontinued - Clinical-Phase-Unknown for Thrombosis in USA (unspecified route)
  • 15 Jun 2004 Discontinued - Phase-II for Unstable angina pectoris in Europe (IV)
  • 15 Jun 2004 Discontinued - Phase-I for Unstable angina pectoris in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top